• Immuron reported publication of Phase 2 results for once-daily oral Travelan in Scientific Reports; data were previously presented on March 7, 2024.
• The trial missed its primary efficacy targets, pressured by an unexpectedly low placebo illness rate that reduced statistical power.
• Across secondary measures, outcomes consistently favored Travelan, pointing to fewer and less severe diarrheal illness versus placebo.
• Safety profile was clean, supporting continued development as a non-antibiotic preventive option for bacterial diarrheal disease.
• Development focus has shifted to a delayed-release, once-daily capsule intended for larger, adequately powered studies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuron Limited published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610130600PRIMZONEFULLFEED9844435) on October 13, 2026, and is solely responsible for the information contained therein.